GlassScriptPhysician profile
Jordan Ganas
NPI 1972093185
$2,811.31
in general payments reported to CMS, 2019-2025
25 companies · $716 in 2025
The $716 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $231 · 2023: $814 · 2024: $899 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $956.52 | 2022-2025 | |
| Ucb, INC. | $393.64 | 2021-2025 | Cimzia, Bimzelx |
| Amgen INC. | $237.08 | 2021-2025 | Evenity, Prolia, Enbrel |
| Novartis Pharmaceuticals Corporation | $206.68 | 2023-2025 | |
| Pfizer INC. | $192.33 | 2023-2025 | |
| Janssen Biotech, INC. | $116.19 | 2023-2024 | Tremfya, Simponi Aria |
| Aurinia Pharma U.S., INC. | $85.62 | 2023-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $74.29 | 2021-2025 | Benlysta |
| Radius Health, INC. | $70.06 | 2023-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.38 | 2024-2025 | Jardiance |
| Ibsa Pharma INC. | $52.27 | 2023-2024 | Tirosint, Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $46.00 | 2023-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $38.52 | 2024 | Purified Cortrophin Gel |
| Ascendis Pharma Endocrinology INC | $34.44 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $33.83 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $30.06 | 2024-2025 | Unithroid |
| E.R. Squibb & Sons, L.L.C. | $24.98 | 2024 | Orencia |
| Abbott Laboratories | $22.35 | 2023 | Freestyle Libre 3 |
| Sandoz INC. | $20.81 | 2023 | Hyrimoz |
| Insulet Corporation | $20.52 | 2025 | Omnipod |
| Tonix Medicines, INC. | $20.35 | 2025 | Tonmya |
| Genentech USA, INC. | $20.25 | 2023 | Actemra |
| Kowa Pharmaceuticals America, INC. | $20.24 | 2023 | Seglentis, Livalo |
| Almatica Pharma LLC | $19.69 | 2024 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $19.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Ganas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.